Journal Watch · Frontiers in Immunology · 2026

Identification of potential therapeutic targets for idiopathic pulmonary fibrosis: an integrated multiomics analysis.

Network analysis linked FN1 to extracellular matrix remodeling and SCARF2 to scavenger receptor-mediated immune regulation, indicating distinct fibrotic and immunomodulatory pathways.<h4>Discussion</h4>These findings identify several potential therapeutic targets for IPF and provide a translational framework for developing disease-modifying therapies that may overcome the limitations of current antifibrotic treatments.

Chen X, Chen S, Zhao S et al.Frontiers in Immunology3 min readPharma relevance 40/100

DOI: 10.3389/fimmu.2026.1754277PMID: 42327717Study type: preclinical (animal / model) study

TL;DR

Network analysis linked FN1 to extracellular matrix remodeling and SCARF2 to scavenger receptor-mediated immune regulation, indicating distinct fibrotic and immunomodulatory pathways.<h4>Discussion</h4>These findings identify several potential therapeutic targets for IPF and provide a translational framework for developing disease-modifying therapies that may overcome the limitations of current antifibrotic treatments.

Key findings

  • Multi-omics integration and experimental validation prioritized four candidate proteins: SCARF2 as a protective factor, and FN1, PPID, and CDON as pro-fibrotic factors.
  • Network analysis linked FN1 to extracellular matrix remodeling and SCARF2 to scavenger receptor-mediated immune regulation, indicating distinct fibrotic and immunomodulatory pathways.<h4>Discussion</h4>These findings identify several potential therapeutic targets for IPF and provide a translational framework for developing disease-modifying therapies that may overcome the limitations of current antifibrotic treatments.

What they did

Causal associations were evaluated using two-sample Mendelian randomization, Steiger filtering, reverse causality testing, and independent dataset validation. Expression-level validation was performed using bleomycin-induced mouse fibrosis and TGF-β1-stimulated fibroblast models.<h4>Results</h4>Twelve proteins were identified as being associated with IPF risk, including eight pro-fibrotic mediators, such as FN1, CCL5, PPID, and CDON, and four protective factors, including SCARF2, IL7R, ESAM, and CD274.

Full abstract (original)

Background: <h4>Introduction</h4>Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by persistent inflammation, aberrant extracellular matrix remodeling, and impaired tissue repair. Current antifibrotic drugs can slow disease progression but cannot reverse established fibrosis, highlighting the need to identify novel mechanism-based therapeutic targets.<h4>Methods</h4>We integrated batch-corrected transcriptomic data from the Gene Expression Omnibus with UK Biobank genome-wide association study statistics, including 1,369 cases and 435,866 controls, and proteomic GWAS instruments for plasma and cerebrospinal fluid proteins.

What they did: Causal associations were evaluated using two-sample Mendelian randomization, Steiger filtering, reverse causality testing, and independent dataset validation. Expression-level validation was performed using bleomycin-induced mouse fibrosis and TGF-β1-stimulated fibroblast models.<h4>Results</h4>Twelve proteins were identified as being associated with IPF risk, including eight pro-fibrotic mediators, such as FN1, CCL5, PPID, and CDON, and four protective factors, including SCARF2, IL7R, ESAM, and CD274.

Results & conclusions: Multi-omics integration and experimental validation prioritized four candidate proteins: SCARF2 as a protective factor, and FN1, PPID, and CDON as pro-fibrotic factors. Network analysis linked FN1 to extracellular matrix remodeling and SCARF2 to scavenger receptor-mediated immune regulation, indicating distinct fibrotic and immunomodulatory pathways.<h4>Discussion</h4>These findings identify several potential therapeutic targets for IPF and provide a translational framework for developing disease-modifying therapies that may overcome the limitations of current antifibrotic treatments.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1754277 · PubMed 42327717.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

Network analysis linked FN1 to extracellular matrix remodeling and SCARF2 to scavenger receptor-mediated immune regulation, indicating distinct fibrotic and immunomodulatory pathways.<h4>Discussion</h4>These findings identify several potential therapeutic targets for IPF and provide a translational framework for developing disease-modifying therapies that may overcome the limitations of current antifibrotic treatments.

What type of study is this?

It is a preclinical (animal / model) study, published in Frontiers in Immunology in 2026. Causal associations were evaluated using two-sample Mendelian randomization, Steiger filtering, reverse causality testing, and independent dataset validation.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1754277. PubMed ID: 42327717. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Chen X, Chen S, Zhao S et al.. Identification of potential therapeutic targets for idiopathic pulmonary fibrosis: an integrated multiomics analysis.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1754277.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/identification-of-potential-therapeutic-targets-for-idiopathic-pulmonary-754277/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides